Research press release




シャーガス病、リーシュマニア症、睡眠病の患者は、全世界に2000万人おり、主にラテンアメリカ、アジア、アフリカの低所得者コミュニティーの住民だ。この3種の疾患は3種の類似した寄生虫を原因としているため、Frantisek Supekたちの研究グループは、1種類の薬物の標的となる共通のタンパク質の同定を目指した。そして、Supekたちは、300万点以上の薬物候補の中から1つの有望な化合物を同定し、その化学構造をさらに精密化して作用強度と生物学的利用能を増強した。


A drug candidate that can rid mice of the parasites that cause Chagas disease, leishmaniasis and sleeping sickness is reported online in Nature this week. The research suggests that a single class of drugs could be used to treat these multiple, neglected diseases, which collectively lead to more than 50,000 human deaths annually.

Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide, primarily in poor communities in Latin America, Asia and Africa. The three diseases are caused by three similar parasites, so Frantisek Supek and colleagues sought to identify a shared protein that could be targeted by a single drug class. From a starting list of over 3 million contenders, they identified one promising compound then refined its chemical structure further to increase its potency and bioavailability.

The drug candidate, named GNF6702, performed well in mouse models of the three diseases, where it appears to work by selectively blocking the activity of the parasite proteasome, a tiny structure involved in protein regulation. Although treatments for Chagas disease, leishmaniasis and sleeping sickness exist, they are expensive, poorly tolerated and of limited effect. The new compound, in contrast, was well tolerated by mice and appears not to disturb the normal functioning of mammalian cells.

doi: 10.1038/nature19339

「Nature 関連誌注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成したリリースを翻訳したものです。より正確かつ詳細な情報が必要な場合には、必ず原著論文をご覧ください。

メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週最新のNature 関連誌のハイライトを皆様にお届けいたします。